## Background: Encouraged by japanese reports of the benefits of screening 6 month-old infants for neuroblastoma, a neuroblastoma screening program was introduced in austria in 1991. however, because of concerns related to "overdiagnosis" by screening at this age, the screening test was performed a
European experience with screening for neuroblastoma before the age of 12 months
โ Scribed by Bergeron, C.; Tafese, T.; Kerbl, R.; Craft, A.; Mann, J.; Frappaz, D.
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 85 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
โฆ Synopsis
If neuroblastoma is a homogeneous disease, a screening program may be appropriate to detect the condition during the preclinical phase, before symptomatic disease, and it may decrease the overall mortality rate. Six pilot European screening studies were performed in infants to study the feasibility (Newcastle, U.K.; Birmingham, U.K.; Stuttgart, Germany; Hamburg, Germany; Lyon,
๐ SIMILAR VOLUMES
## Abstract This prospective study was designed to estimate the response rates and to compare two drug pairs, cyclophosphamide/doxorubicin (Cy/A) and cisplatin/teniposide (P1/VM) in previously untreated patients with disseminated neuroblastoma >12 months of age at diagnosis. Estimated complete clin